<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medgen</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская генетика</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Genetics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-7998</issn><publisher><publisher-name>Publishing House «Genius Media» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25557/2073-7998.2022.11.62-66</article-id><article-id custom-type="elpub" pub-id-type="custom">medgen-2203</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКОЕ СООБЩЕНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BRIEF REPORT</subject></subj-group></article-categories><title-group><article-title>Комплексный анализ метилирования генов р53-респонзивных микроРНК и мутаций гена ТР53 при диффузной В-крупноклеточной лимфоме</article-title><trans-title-group xml:lang="en"><trans-title>Complex analysis of p53-responsive microRNA genes methylation and TР53 gene mutations in Diffuse Large B-cell Lymphoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воропаева</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Voropaeva</surname><given-names>E. N.</given-names></name></name-alternatives><email xlink:type="simple">vena.81@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поспелова</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Pospelova</surname><given-names>T. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чуркина</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Churkina</surname><given-names>M. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуражева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurazheva</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воевода</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Voevoda</surname><given-names>M. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Maximov</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт терапии и профилактической медицины - филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Internal and Preventive Medicine - Branch of the «Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>01</month><year>2023</year></pub-date><volume>21</volume><issue>11</issue><fpage>62</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Воропаева Е.Н., Поспелова Т.И., Чуркина М.И., Гуражева А.А., Воевода М.И., Максимов В.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Воропаева Е.Н., Поспелова Т.И., Чуркина М.И., Гуражева А.А., Воевода М.И., Максимов В.Н.</copyright-holder><copyright-holder xml:lang="en">Voropaeva E.N., Pospelova T.I., Churkina M.I., Gurazheva A.A., Voevoda M.I., Maximov V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medgen-journal.ru/jour/article/view/2203">https://www.medgen-journal.ru/jour/article/view/2203</self-uri><abstract><p>Актуальность. Сравнение экспрессии микроРНК в опухолевой ткани лимфом и нормальной лимфоидной ткани выявило снижение уровня экспрессии ряда р53-индуцируемых онкосупрессорных молекул, таких как микроРНК-34a, микроРНК-34b/c, микроРНК-129 и микроРНК-203, которое помимо мутаций в гене ТР53 может быть вызвано аберрациями в участках генома, кодирующих сами микроРНК. Цель. Провести комплексный анализ метилирования генов р53-респонзивных микроРНК MIR-34А, MIR-34В/С, MIR-203 и MIR-129-2 и мутаций гена ТР53 при диффузной В-клеточной крупноклеточной лимфоме (ДВККЛ). Методы. Проанализировано 73 образца ДНК, выделенной из опухолевой ткани пациентов с ДВККЛ. Методом капиллярного прямого секвенирования по Сэнгеру определена нуклеотидная последовательность ДНК-связывающего домена гена ТР53. Определение статуса метилирования осуществляли методами метил-специфичной ПЦР (для MIR-203 и MIR-129-2) и метил-чувствительного анализа кривых плавления высокого разрешения (для MIR-34А и MIR-34В/С) с применением ДНК, подвергшейся обработке бисульфитом натрия. Результаты. Частота метилирования генов MIR-34А, MIR-34В/С, MIR-203 и MIR-129-2 и мутации в гене ТР53 составила 27%, 62%, 66%, 67% и 25%, соответственно. Метилирование анализируемых генов р53-респонзивных микроРНК и мутации в гене ТР53 в опухолевой ткани ДВККЛ у большей части пациентов имели тенденцию к взаимному исключению. Показана значимая ассоциация (р&lt;0,05) между метилированием генов MIR-203, MIR-129-2 и MIR-34B/C, а также парой MIR-34B/C и MIR-34A. В 14% случаев имело место метилирование всех 4, а в 47% - 3 проанализированных генов. Выводы. Наряду с мутациями в гене ТР53, аберрантное метилирование может являться самостоятельной причиной снижения экспрессии микроРНК-34a, микроРНК-34b/c, микроРНК-129 и микроРНК-203. Метилирование генов MIR-34А, MIR-34В/С, MIR-203 и MIR-129-2 в опухолевой ткани ДВККЛ в большинстве случаев носит сочетанный характер.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Comparison of microRNA expression in lymphoma and normal lymphoid tissue revealed a decrease in the expression level of a number of p53-induced oncosuppressive molecules, such as miR-34a, miR-34b/c, miR-129 and miR-203, which, in addition to mutations in the TP53 gene, can be caused by aberrations in the genome regions encoding the microRNAs themselves. Purpose. To carry out a comprehensive analysis of the p53-responsive microRNAs genes MIR-34A, MIR-34B/C, MIR-203 and MIR-129-2 methylation and mutations of the TP53 gene in diffuse large B-cell lymphoma (DLBCL). Methods. 73 samples of DNA isolated from tumor tissue of patients with DLBCL were analyzed. The nucleotide sequence of the TP53 gene DNA-binding domain was determined by capillary direct Sanger sequencing. The methylation status was determined by methyl-specific PCR (for MIR-203 and MIR-129-2) and methyl-sensitive analysis of high-resolution melting curves (for MIR-34A and MIR-34B/C) using DNA treated with sodium bisulfite. Results. The frequency of MIR-34A, MIR-34B/C, MIR-203 and MIR-129-2 genes methylation and TP53 gene mutations was 27%, 62%, 66%, 67% and 25%, respectively. Methylation of the analyzed genes of p53-responsive microRNAs and mutations in the TP53 gene in the tumor tissue of DLBCL in the most patients tended to mutual exclusion. A significant association (p &lt; 0.05) was shown between the methylation of the MIR-203, MIR-129-2 and MIR-34B/C genes, as well as the MIR-34B/C and MIR-34A pair. In 14% and 47% of DLBCL cases all four genes and three of the analyzed genes were methylated, respectively. Conclusions. Along with mutations in the TP53 gene aberrant methylation may be an independent cause of decreased miR-34a, miR-34b/c, miR-129 and miR-203 expression. Methylation of the MIR-34A, MIR-34B/C, MIR-203 and MIR-129-2 genes in the tumor tissue of DLBCL in most cases is of a combined nature.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ген ТР53</kwd><kwd>микроРНК</kwd><kwd>метилирование</kwd><kwd>микроРНК-34a</kwd><kwd>микроРНК-34b/c</kwd><kwd>микроРНК-129</kwd><kwd>микроРНК-203</kwd><kwd>лимфома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ТР53 gene</kwd><kwd>microRNA</kwd><kwd>methylation</kwd><kwd>miR-34a</kwd><kwd>miR-34b/c</kwd><kwd>miR-129</kwd><kwd>miR-203</kwd><kwd>lymphoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arribas A.J., Gómez-Abad C., Sánchez-Beato M. et al. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013;26(7):889-901.</mixed-citation><mixed-citation xml:lang="en">Arribas A.J., Gómez-Abad C., Sánchez-Beato M. et al. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013;26(7):889-901.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Craig V.J., Cogliatti S.B., Rehrauer H. et al. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res. 2011;71(10):3616-24.</mixed-citation><mixed-citation xml:lang="en">Craig V.J., Cogliatti S.B., Rehrauer H. et al. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res. 2011;71(10):3616-24.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Воропаева Е.Н., Березина О.В., Чуркина М.И. и др. Аберрантная экспрессия и метилирование генов отдельных микроРНК при лимфопролиферативных заболеваниях: обзор литературы. Journal of Siberian Medical Sciences. 2021; 4:108-133.</mixed-citation><mixed-citation xml:lang="en">Воропаева Е.Н., Березина О.В., Чуркина М.И. и др. Аберрантная экспрессия и метилирование генов отдельных микроРНК при лимфопролиферативных заболеваниях: обзор литературы. Journal of Siberian Medical Sciences. 2021; 4:108-133.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Воропаева Е.Н., Поспелова Т.И., Березина О.В. и др. Метилирование генов р53-респонзивных онкосупрессорных микроРНК при гемобластозах. Сибирский онкологический журнал. 2022;21(2):130-142.</mixed-citation><mixed-citation xml:lang="en">Воропаева Е.Н., Поспелова Т.И., Березина О.В. и др. Метилирование генов р53-респонзивных онкосупрессорных микроРНК при гемобластозах. Сибирский онкологический журнал. 2022;21(2):130-142.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Solé C., Larrea E., Di PG. et al. miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. Cancer Lett. 2017; 405: 79-89.</mixed-citation><mixed-citation xml:lang="en">Solé C., Larrea E., Di PG. et al. miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. Cancer Lett. 2017; 405: 79-89.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gao J., Aksoy B.A., Dogrusoz U. et al.Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal. 2013;6(269):pl1.</mixed-citation><mixed-citation xml:lang="en">Gao J., Aksoy B.A., Dogrusoz U. et al.Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal. 2013;6(269):pl1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Piovan C., Palmieri D., Di Leva G. et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6(4):458-72.</mixed-citation><mixed-citation xml:lang="en">Piovan C., Palmieri D., Di Leva G. et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6(4):458-72.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Larrabeiti-Etxebarria A., Lopez-Santillan M., Santos-Zorrozua B. et al. A Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma. Cancers (Basel). 2019;11(2):144.</mixed-citation><mixed-citation xml:lang="en">Larrabeiti-Etxebarria A., Lopez-Santillan M., Santos-Zorrozua B. et al. A Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma. Cancers (Basel). 2019;11(2):144.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
